QUEST DIAGNOSTICS INC

DGX

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Casdin Capital Deerfield Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Casdin CapitalNEWFeb 17, 2026

Shares: 50,000Value: $8.7M

# Signal Note: Casdin Capital Initiates DGX Position Casdin's $8.7M entry into Quest Diagnostics suggests conviction in consolidation plays within clinical diagnostics infrastructure, likely tied to secular tailwinds in precision medicine adoption and potential M&A activity in the fragmented lab testing space. The positioning aligns with Casdin's genomics/tools thesis, as Quest's scale in specimen processing and data could unlock value in emerging molecular diagnostic workflows. No near-term catalyst is apparent, suggesting a multi-year thesis on diagnostic volume growth and operational leverage post-pandemic normalization.

Deerfield ManagementNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

CI2 funds ALNY2 funds BLFS2 funds LEGN2 funds GPCR2 funds RVMD2 funds TXG2 funds VCYT

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Deerfield Initiates DGX Position **Key Signal:** Deerfield Management's $3.2M entry into Quest Diagnostics signals conviction in diagnostic testing demand, likely driven by anticipated volume recovery in routine/wellness testing post-pandemic normalization and potential M&A consolidation tailwinds in the $200B+ clinical lab market. The position size reflects opportunistic entry rather than major thesis shift, suggesting DGX valuation reached acceptable risk/reward on recent weakness or specific operational catalyst visibility.